Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABMSCi for Liver Diseases
NCT02943707Phase 2Unknown
- Sponsor
- Wenzhou Medical University
- Start
- Oct 2016
- Primary completion
- Oct 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous bone marrow stem cells in liver disease, sponsored by Wenzhou Medical University. Primary endpoints: Alanine Aminotransferase at 6 months and Aspartate Aminotransferase at 6 months. Status: unknown.
02
Drugs
autologous bone marrow stem cells
03
Conditions
liver disease
Beyond the preview
Go deeper on NCT02943707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02943707.